Neurolieve Biosciences Ltd
Neurolieve Biosciences has the ambition to bringing innovative break-through therapy aiming at ameliorating the quality of life of millions of patients suffering from peripheral neuropathy
Neurolieve Biosciences is a pre-clinical stage company developing an innovative lead drug compound candidate, Fc2-13 GalR2, for the treatment of neuropathic pain. Fc2-13 GalR2 is a bioengineered biologic protein (FC fusion protein) deriving from a type I receptor combined with the Fc domain of a human Ig G1 rendering itself as attractive biotherapeutic agent. The ability of GalR2 activation (agonism) to reduce the excitability of peripheral neurons and produce an analgesic effect makes it a promising and attractive novel target for the development of therapeutic options for neuropathic pain.
Neurolieve Biosciences is approaching a final pre-clinical stage and has the ambition to entering into FIH study after completion of GLP toxicology study.
Neurolieve Biosciences is approaching a final pre-clinical stage and has the ambition to entering into FIH study after the completion of last non-clinical studies. Peripheral Neuropathy is a common and often debilitating neurological disorder affecting millions of people that refers to a group of conditions that involve damage to the peripheral nervous system and leads to severe discomfort that significantly deteriorates the quality of life. The complexity of neuropathic pain and its varied causes – from diabetes to chemotherapy – make it a stubborn and multifaceted health challenge.
Fc-13 GalR2 might represent a new frontier being utilized to develop tailored smart therapeutics for neuropathic pain.
Neurolieve Biosciences is striving to provide with a groundbreaking, bioengineered protein-based therapy (Fc-13 GalR2) showing an accumulation on DRG (Dorsal Root Ganglia) and lack of CNS blood brain barrier penetrance. Fc-13 GalR2 might represent a new frontier being utilized to develop tailored smart therapeutics for peripheral neuropathy. This novel solution directly interacts with nerve cell mechanisms to decrease pain sensitivity and is designed to target the pain at its source. It offers the potential for substantial pain relief without the common side effects, representing a significant leap forward in neuropathic pain management
Neurolieve Biosciences: Advancing to Pre-Clinical Stage with Promising Results in Rodent Disease Models”
Neurolieve Biosciences is currently at a pre-clinical stage after being successful in leading in vitro characterization and multiple in vivo studies in several rodent disease models (CCI/CFA efficacy model).
